HRMY Harmony Biosciences Holdings, Inc.
Healthcare$30.09-0.20%ClosedMarket Cap: $1.74B
As of 2026-05-26
Valuation
P/E (TTM)
10.53
PEG
1.16
P/B
1.91
P/S
1.94
EV/EBITDA
5.84
DCF Value
$116.24
FCF Yield
19.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.5%
Operating Margin
21.1%
Net Margin
16.2%
ROE
17.2%
ROA
11.4%
ROIC
12.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $215.4M | 79.3% | $37.3M | $32.5M | $— | — |
| Q4 null | $243.8M | 71.9% | $38.6M | $22.5M | $— | — |
| FY null | $868.5M | 77.2% | $208.5M | $158.7M | $— | — |
| Q3 null | $239.5M | 75.1% | $65.5M | $50.9M | $— | — |
| Q2 null | $200.5M | 81.0% | $48.2M | $39.8M | $— | — |
| Q1 null | $184.7M | 82.7% | $56.2M | $45.6M | $— | — |
| Q4 null | $201.3M | 73.0% | $55.7M | $49.5M | $— | — |
| FY null | $714.7M | 78.1% | $190.8M | $145.5M | $— | — |
| Q3 null | $186.0M | 77.0% | $61.7M | $46.1M | $— | — |
| Q2 null | $172.8M | 81.4% | $21.4M | $11.6M | $— | — |
| Q1 null | $154.6M | 82.2% | $52.0M | $38.3M | $— | — |
| Q4 2023 | $168.4M | 74.4% | $40.2M | $26.6M | $0.45 | — |